3H-咪唑并[2,1-c][1,4]恶嗪 | 43031-31-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪类
• 中文名称: 3H-咪唑并[2,1-c][1,4]恶嗪
• 英文名称: 3H-Imidazo[2,1-c][1,4]oxazine
• CAS: 43031-31-8
• 化学式: C₆H₆N₂O
• 分子量: 122.12
• InChiKey: UGICTLUNXXOGOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  24.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors
  申请人：Pfizer Inc.

  公开号：US20170073343A1

  公开（公告）日：2017-03-16

  The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R 1 , R 1a , R 1b , R 2 , R 4 , R 5 , R 6 , X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了新颖的咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啉衍生物的化合物(I)及其药学上可接受的盐，其中R1、R1a、R1b、R2、R4、R5、R6、X和Z如规范中所定义。该发明还涉及包含化合物(I)的药物组合物，以及利用这些化合物治疗与LRRK2相关的疾病，如神经退行性疾病包括帕金森病或阿尔茨海默病、癌症、克罗恩病或麻风病。
• Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
  申请人：Pfizer Inc.

  公开号：US10039753B2

  公开（公告）日：2018-08-07

  The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了式 (I) 的新型咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物及其药学上可接受的盐类 其中 R1、R1a、R1b、R2、R4、R5、R6、X 和 Z 如说明书中所定义。本发明还涉及包含式（I）化合物的药物组合物，以及该化合物在治疗与 LRRK2 有关的疾病中的用途，如神经退行性疾病，包括帕金森病或阿尔茨海默病、癌症、克罗恩病或麻风病。
• ANTIRETROVIRAL AGENTS
  申请人：Gilead Sciences, Inc.

  公开号：EP3186239A1

  公开（公告）日：2017-07-05
• SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES
  申请人：Recurium IP Holdings, LLC

  公开号：EP3762385A1

  公开（公告）日：2021-01-13
• [EN] ANTIRETROVIRAL AGENTS<br/>[FR] AGENTS ANTIRÉTROVIRAUX
  申请人：GILEAD SCIENCES INC

  公开号：WO2016033243A1

  公开（公告）日：2016-03-03

  Compounds of formula I or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.